KR102687556B1 - 종양 전이를 억제하는 방법 - Google Patents

종양 전이를 억제하는 방법 Download PDF

Info

Publication number
KR102687556B1
KR102687556B1 KR1020207017233A KR20207017233A KR102687556B1 KR 102687556 B1 KR102687556 B1 KR 102687556B1 KR 1020207017233 A KR1020207017233 A KR 1020207017233A KR 20207017233 A KR20207017233 A KR 20207017233A KR 102687556 B1 KR102687556 B1 KR 102687556B1
Authority
KR
South Korea
Prior art keywords
pharmaceutical composition
cancer
metastasis
tumor
ifetroban
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020207017233A
Other languages
English (en)
Korean (ko)
Other versions
KR20200093575A (ko
Inventor
질 엠. 풀리
로버트 알. 라비에리
Original Assignee
반더빌트유니버시티
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 반더빌트유니버시티 filed Critical 반더빌트유니버시티
Publication of KR20200093575A publication Critical patent/KR20200093575A/ko
Application granted granted Critical
Publication of KR102687556B1 publication Critical patent/KR102687556B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020207017233A 2017-11-29 2018-11-29 종양 전이를 억제하는 방법 Active KR102687556B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762592365P 2017-11-29 2017-11-29
US62/592,365 2017-11-29
PCT/US2018/062967 WO2019108736A1 (en) 2017-11-29 2018-11-29 Methods of inhibiting tumor metastasis

Publications (2)

Publication Number Publication Date
KR20200093575A KR20200093575A (ko) 2020-08-05
KR102687556B1 true KR102687556B1 (ko) 2024-07-22

Family

ID=66664589

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020207017233A Active KR102687556B1 (ko) 2017-11-29 2018-11-29 종양 전이를 억제하는 방법

Country Status (9)

Country Link
US (4) US11471444B2 (https=)
EP (1) EP3716973A4 (https=)
JP (1) JP7305197B2 (https=)
KR (1) KR102687556B1 (https=)
CN (2) CN111432817B (https=)
AU (1) AU2018375378A1 (https=)
CA (1) CA3082839A1 (https=)
TW (1) TW201924719A (https=)
WO (1) WO2019108736A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220164000A (ko) * 2020-03-31 2022-12-12 어플라이드 메디칼 테크놀로지스 엘엘씨 Pgd2/dp2 및 트롬복산 a2/tp 수용체의 이중 길항제 및 이상 면역 반응 또는 혈전성 체질의 치료를 위한 이의 용도

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5066480A (en) 1988-04-11 1991-11-19 E. R. Squibb & Sons, Inc. Method of preventing or reducing adverse reactions to protamine using a thromboxane a2 receptor antagonist
US4839384A (en) 1988-10-07 1989-06-13 E. R. Squibb & Sons, Inc. Method of inhibiting onset of or treating migraine headache using a thromboxane A2 receptor antagonist
US5153327A (en) 1988-12-23 1992-10-06 E. R. Squibb & Sons, Inc. 7-Oxabicycloheptyl substituted heterocyclic amide or ester prostaglandin analogs useful in the treatment of thrombotic and vasospastic disease
US5100889A (en) 1989-04-03 1992-03-31 E. R. Squibb & Sons, Inc. 7-oxabicycloheptyl substituted heterocyclic amide or ester prostaglandin analogs useful in the treatment of thrombotic and vasospastic disease
ZA911453B (en) 1990-03-19 1991-11-27 Squibb & Sons Inc Method of protecting against and/or treating ulcerative gastrointestinal conditions using a thromoboxane,a2 receptor antagonist and combination useful in preventing and/or treating ulcers and/or inflammation
US5158967A (en) * 1991-06-12 1992-10-27 E. R. Squibb & Sons, Inc. 7-oxabicycloheptyl substituted heterocyclic amide prostaglandin analogs useful in the treatment of thrombotic and vasospastic disease
US5281716A (en) * 1992-06-18 1994-01-25 Bristol-Myers Squibb Company Method for preparing 7-oxabicycloheptyl substituted oxazole amide prostaglandin analog intermediates useful in the preparation of anti-thrombotic and anti-vasospastic compounds
US5260449A (en) 1992-08-12 1993-11-09 E. R. Squibb & Sons, Inc. Method for preparing 7-oxabicycloheptyl substituted bromooxazole amide prostaglandin analog intermediates useful in the preparation of anti-thrombotic and anti-vasospastic compounds
US5399725A (en) 1993-05-27 1995-03-21 Bristol-Myers Squibb Co. 7-oxabicycloheptane carboxylic acid prostaglandin analog intermediates useful in the preparation of anti-thrombotic and anti-vasospastic compounds and method for preparing same
US5332840A (en) 1993-05-27 1994-07-26 Bristol-Myers Squibb Company Method for preparing a benzaldehyde intermediate
US5605917A (en) 1994-12-22 1997-02-25 Bristol-Myers Squibb Company Method of treating dysmenorrhea employing an interphenylene 7-oxabicycloheptyl substituted heterocyclic amide prostaglandin analog
IL137937A0 (en) 1999-08-27 2001-10-31 Pfizer Prod Inc A pharmaceutical composition for the prevention and treatment of nicotine addiction in a mammal
AU2001264729A1 (en) * 2000-05-22 2001-12-03 Nitromed, Inc. Thromboxane inhibitors, compositions and methods of use related applications
KR100681763B1 (ko) 2005-02-28 2007-02-15 재단법인 목암생명공학연구소 인간 리포칼린 2를 유효성분으로 포함하는 암 전이 억제용약학적 조성물, 이를 이용한 암 전이 억제 방법
EP1986675A2 (en) 2006-02-24 2008-11-05 The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services Extracellular matrix/metastasis modifer genes for the prevention or inhibition of metastasis or growth of tumor and for characterization of tumor
US20080160024A1 (en) 2006-12-07 2008-07-03 Board Of Trustees Of The University Of Arkansas Inhibition of cancer metastasis
WO2009089098A1 (en) 2008-01-03 2009-07-16 Musc Foundation For Research Development Methods for the treatment of cancers
US9283266B2 (en) 2008-02-28 2016-03-15 University Of Notre Dame Metastasis inhibition preparations and methods
US8912167B2 (en) 2011-05-19 2014-12-16 Eugene J. Oliva Heparin-based compositions and methods for the inhibition of metastasis
US20170226514A1 (en) 2014-08-13 2017-08-10 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Prevention of tumour metastasis by inhibition of necroptosis

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Cancer Research 72(8):3445(2012)
Cardiovascular drug reviews 19(2):97-115(2001)

Also Published As

Publication number Publication date
CN117122687A (zh) 2023-11-28
JP2021504385A (ja) 2021-02-15
EP3716973A1 (en) 2020-10-07
US20250144079A1 (en) 2025-05-08
CN111432817A (zh) 2020-07-17
KR20200093575A (ko) 2020-08-05
AU2018375378A1 (en) 2020-05-28
US20240041839A1 (en) 2024-02-08
US11471444B2 (en) 2022-10-18
US20230090578A1 (en) 2023-03-23
WO2019108736A1 (en) 2019-06-06
US20200405694A1 (en) 2020-12-31
JP7305197B2 (ja) 2023-07-10
CA3082839A1 (en) 2019-06-06
CN111432817B (zh) 2023-10-31
EP3716973A4 (en) 2021-11-10
TW201924719A (zh) 2019-07-01

Similar Documents

Publication Publication Date Title
CN111170991A (zh) 抗增殖化合物及其合成方法
TWI818954B (zh) 三取代之苯并三唑衍生物的使用方法
EP1411984B1 (en) Combination medicament for treatment of neoplastic diseases which contains cyanoguanidine ikk inhibitors and a second anti-neoplastic drug
AU2002316795A1 (en) Combination medicament for treatment of neoplastic diseases containing cyanoguanidine IKK inhibitors and a second anti-neoplastic drug
KR20170015507A (ko) 암을 치료하는 조성물 및 방법
KR102275112B1 (ko) 5-브로모-인디루빈
CA2884832C (en) Means and method for treating solid tumours
US20250144079A1 (en) Methods of inhibiting tumor metastasis
JP6063472B2 (ja) 骨髄増殖性新生物形成および慢性骨髄性白血病を含む、トランスデューシンβ様タンパク質１（ＴＢＬ１）活性に関連する疾患および障害の処置のための方法
CN103251585B (zh) 青蒿素及其衍生物在抑制血小板衍生生长因子受体a中的作用及其应用
WO2014183673A1 (zh) 阿那格雷及其衍生物的抗肿瘤用途
JP2019519573A (ja) がんを処置するための方法
RU2731535C1 (ru) Комбинация, ее применение и способ лечения
TW201343169A (zh) 使用奧諾拉（ａｕｒｏｒａ）激酶抑制劑治療癌症的方法
WO2013107225A1 (zh) N-（（4-氯-3-三氟甲基）苯基）-n'-（2-氟-4-（（2-羟甲基氨基甲酰基)-4-吡啶基氧）苯基）脲及其作为抗癌药物的应用
HK40033357A (en) Methods of inhibiting tumor metastasis
KR20130012253A (ko) 간세포암 치료를 위한 항종양제 또는 수술 후 보조 화학 요법제
CN106176757B (zh) 一种化合物与替吉奥联合在制备治疗增生性疾病中的药物中的用途
HK40029947A (en) Antiproliferative compounds and methods of synthesizing thereof
BR112019028226B1 (pt) Agente antitumoral que compreende um composto azabiciclo em combinação com um regulador da molécula de checkpoint imunológico, agente potencializador de efeito antitumoral para o dito regulador, imunoestimulante e usos dos ditos composto e regulador para tratar câncer
BR122025010361A2 (pt) Agente antitumoral compreendendo um composto azabiciclo em combinação com um regulador da molécula de checkpoint imunológico, agente potencializador de efeito antitumoral para o dito regulador, imunoestimulante e usos dos ditos composto e regulador
CN102675370A (zh) 一种用于治疗癌症的新化合物

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20200616

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20211124

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20231127

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20240705

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20240718

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20240718

End annual number: 3

Start annual number: 1

PG1601 Publication of registration